BJR
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
First published online May 11, 2009
British Journal of Radiology (2009) 82, 860-876
© 2009 British Institute of Radiology
doi: 10.1259/bjr/25645894
This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Google Scholar
Right arrow Articles by WONG, K K
Right arrow Articles by AVRAM, A M
PubMed
Right arrow PubMed Citation
Right arrow Articles by WONG, K K
Right arrow Articles by AVRAM, A M

Hybrid SPECT–CT and PET–CT imaging of differentiated thyroid carcinoma

K K WONG, MBBS N ZARZHEVSKY, MD J M CAHILL, MBChB K A FREY, MD, PhD and A M AVRAM, MD

Nuclear Medicine/Radiology, University of Michigan, Ann Arbor, Michigan, USA

Correspondence: Ka Kit Wong, Department of Nuclear Medicine/Radiology, University of Michigan, 1500 E. Medical Center Drive, B1G505 UH, Ann Arbor, MI 48109–0028, USA. E-mail: kakitw{at}hotmail.com

Hybrid imaging modalities such as radioiodine single photon emission CT with integrated CT (131I SPECT–CT) and 2-(fluorine-18)-fluoro-2-deoxy-D-glucose positron emission tomography with integrated CT (FDG PET–CT) allow the rapid and efficient fusion of functional and anatomic images, and provide diagnostic information that may influence management decisions in patients with differentiated thyroid carcinoma (DTC). Diagnostic localisation and therapy of these tumours are dependent upon their capacity to concentrate radioiodine (131I) via uptake through the sodium–iodide symporter and retention within the tumour. The prognosis for most patients with DTC is favourable, although controversy exists regarding the role of post-operative 131I therapy in patients at low-risk for disease. Accurate identification of functional thyroid tissue (benign or malignant) using diagnostic 131I planar scintigraphy complemented by SPECT–CT imaging enables the completion of post-operative staging and patient risk stratification prior to 131I therapy administration. In patients with non-iodine-avid tumours (negative 131I scan but elevated thyroglobulin indicative of persistent or recurrent disease), FDG PET–CT is used to identify tumours with enhanced glucose metabolism and to localise the source of thyroglobulin production. The CT component of this hybrid technology provides anatomic localisation of activity and allows CT-based attenuation correction of PET images. Images from 15 patients illustrate the applications of 131I SPECT–CT and FDG PET–CT.






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
BJR DMFR IMAGING  ALL BIR JOURNALS 
Copyright © 2009 by the British Institute of Radiology.